Progeria (Hutchinson–Gilford progeria syndrome)

Key signs and features

Children with progeria are usually born appearing normal but begin to show signs within the first two years. Typical features include slow growth and short stature, loss of subcutaneous fat, hair loss (alopecia), thin skin with pronounced wrinkles, a small jaw, and visible scalp veins. Intelligence is usually normal. Cardiovascular disease—accelerated atherosclerosis leading to heart attack or stroke—is the most serious complication.

• Growth failure and low weight
• Distinctive facial appearance (prominent eyes, small jaw)
• Hair thinning or baldness
• Stiff joints and limited mobility
• Early-onset cardiovascular disease

Progeria belongs to a broader group of conditions called progeroid syndromes; these share some features but arise from different causes and follow different courses. For context, see progeroid syndromes.

Cause and biological mechanism

The classic form of progeria is most commonly caused by a spontaneous (de novo) mutation in the LMNA gene. This mutation produces an abnormal form of the nuclear structural protein lamin A, commonly referred to as "progerin." Progerin accumulates in cell nuclei and disrupts nuclear architecture, DNA repair, and normal cell function, which is thought to underlie many of the disease features. The change almost always arises anew in the affected child rather than being inherited from a parent; for information on inheritance and genetic testing see genetics resources.

Course, frequency, and prognosis

Progeria is very rare—often cited as occurring in roughly one in several million births—and life expectancy is reduced, with many affected individuals living into their mid-teens to early twenties. The primary life-limiting problem is cardiovascular disease caused by premature hardening of the arteries. Management focuses on monitoring and treating cardiovascular risk, addressing feeding and growth problems, and supporting mobility and joint function.

History, research, and treatments

The first clinical descriptions of the syndrome date to the late 19th century by Jonathan Hutchinson and later by Hastings Gilford, which is why the condition bears both their names. Molecular understanding advanced in the early 21st century when researchers identified the LMNA-related defect that produces progerin. That discovery spurred laboratory research into how nuclear structure affects aging and prompted clinical trials of targeted therapies. One medication, a farnesyltransferase inhibitor, has shown benefits in clinical studies and has been used as a directed treatment, though care remains largely supportive and experimental approaches continue to be evaluated.

Importance and distinctions

Progeria is scientifically important because its cellular mechanisms overlap with pathways studied in normal aging, offering a window into processes like DNA repair, nuclear maintenance, and vascular aging. However, it is not simply accelerated ordinary aging—many organs age differently and certain age-related diseases seen in the elderly do not mirror the pediatric course. Families and clinicians often work with specialized centers and advocacy groups to manage care and participate in research; historical and language notes on the term trace back to the Greek roots for "before" and "old age" as reflected in the condition's name (etymology).